New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 4, 2014
12:06 EDTSGNTSagent Pharmaceuticals initiates voluntary recall of Zoledronic Acid lots
Sagent Pharmaceuticals announced the voluntary nationwide recall of two lots of Zoledronic Acid Injection, 5mg/100mL premix bag (NDC number 25021-830-82) distributed by Sagent. Sagent has initiated this voluntary recall of Zoledronic Acid Injection, 5mg/100mL to the user level due to the discovery of four leaking premix bags detected during an investigation conducted in response to a product complaint. The subject bags were not administered to patients as the leakage was readily apparent. A non-integral premix bag can result in a lack of sterility assurance. Sagent is not aware of any adverse patient events resulting from the use of this product and is continuing its investigation of the situation. The lots being recalled are numbers 30076 and 30077 which were distributed to hospitals, wholesalers and distributors nationwide from October 9, 2013 through February 18, 2014. Zoledronic Acid Injection, 5mg/100mL is a bisphosphonate indicated for the treatment of Paget's disease of bone in men and women and is supplied in a premix bag. Sagent's distributor DDN (DOHMEN Life Science Services) is notifying Sagent's distributors and customers by fax, email and certified mail and is arranging for return of all recalled product.Customers have been instructed to examine their inventory immediately and to quarantine, discontinue distribution of and return the recalled lots of product. Customers who may have further distributed this product have been requested to identify their customers and notify them at once of this product recall.
News For SGNT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 17, 2014
12:57 EDTSGNTOn The Fly: Midday Wrap
Subscribe for More Information
07:32 EDTSGNTSagent FY15 guidance could be 'well below' consensus, says Jefferies
Jefferies says it sees several reasons why Sagent Pharmaceuticals' upcoming FY15 guidance could fall "well below" consensus estimates. The firm believes the launch of g-Venofer and g-Nembutal could be delayed until FY16, and it thinks Sagent's base business could see enhanced competition in FY15. Jefferies lowered its price target for shares to $27 from $33 and keeps a Hold rating on the name.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use